Our results also first demonstrated that in vitro induction of Treg cells from sorted naïve CD4 T cells by VPA can be used in the cell therapy for the treatment of T1D patients in order to avoid the toxicity of in vivo VPA treatment. The gene discussed is CD4; the disease is type 1 diabetes mellitus.